PBAC plan to restrict diabetes drug prescribing ‘inconsistent with guidelines’
Associate Professor Neale Cohen also criticised the PBAC for rejecting a potential PBS listing for tirzepatide.
A proposed PBS crackdown on GLP-1 receptor agonists is inconsistent with type 2 diabetes management guidelines and will force doctors to prescribe less efficacious drugs, says a leading endocrinologist.
Following its July meeting, the PBAC has said subsidies for dulaglutide and semaglutide should be restricted to patients with contraindications, intolerance or inadequate response to SGLT-2 inhibitor therapy.
